✉news HealthMedicine first seen 10 h ago, last 5 h ago, peak #2
Laverock Therapeutics unveils in vivo programmes in oncology and genetic medicine
Original: Laverock Therapeutics announces in vivo programmes in oncology and genetic medicine
UK-based gene therapy company Laverock Therapeutics has announced new in vivo programmes focused on oncology and genetic medicine, expanding its pipeline of RNA-based therapies designed to be delivered directly into patients. The company says the move broadens its therapeutic reach beyond earlier ex vivo work, though further details on targets and timelines were not immediately provided.
Why now: The biotech sector is watching gene-editing companies as they expand into in vivo delivery, a major step toward treating cancers and genetic diseases directly.
Rank over time, top of the chart is #1. 4 snapshots from 10 h ago to 5 h ago.
Evidence
API: https://socialmediatrends-api.osmike.com/v1/trends/486652